James V Cassella
CIK 1353528 · Chief Development Officer · last filed 2026-02-20
James V Cassella is a Chief Development Officer who has filed 59 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for TRVI, was dated Feb 20, 2026. Across all open-market trades the lifetime net is −$658.5K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
3
59
-$658.5K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRVI | Chief Development Officer | — | $14.21 | — | $0 | 9 | 2026-02-20 |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Chief Development Officer | 0 | $8.37 | $0 | -$470.3K | 23 | 2023-03-06 |
| Alexza Pharmaceuticals Inc. (ALXA) Delisted | Former EVP, R&D and CSO | 18,745 | — | — | -$188.2K | 27 | 2015-05-04 |
Recent Filings
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-20 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2025-02-20 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2024-10-01 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2023-06-30 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2023-03-06 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Mixed | −138,361 | $0 | EDGAR |
| 2023-02-16 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Sell (S) | −3,762 | -$31.4K | EDGAR |
| 2023-01-31 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Sell (S) | −10,106 | -$84.4K | EDGAR |
| 2023-01-09 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Sell (S) | −2,893 | -$21.0K | EDGAR |
| 2022-07-01 | TRVI | Grant (A) | — | $0 | EDGAR |